

Table S6. Antitumor efficacy of BAY 1905254 and anti-PD-L1 in monotherapy or in combination in a panel of syngeneic mouse models shown as T/C values.

Model	Mouse strain	Cancer type	Dosing (initiation of treatment)	T/C BAY 1905254	T/C anti-PD-L1	T/C BAY 1905254 + anti-PD-L1
3C9-D11-H11	BALB/c	Mouse myeloma	10 mg/kg Q3Dx5 (day 8)	0.87	0.39**	0.07***
B16F10	C57BL/6N	Mouse melanoma	10 mg/kg Q3Dx6 (day 0)	0.63*	n.d.	n.d.
B16F10	C57BL/6N	Mouse melanoma	10 mg/kg Q3Dx5 (day 3)	1.08	0.92	0.65*
B16F10-OVA	C57BL/6N	Mouse melanoma	10 mg/kg Q3Dx3 (day 8)	0.66	0.40**	0.29***
B16F10-OVA + OT-I	NCI B6-Ly5.1	Mouse melanoma	12 mg/kg ^a Q3Dx4 (day 8)	1.16	0.59**	0.30***
CT26	BALB/c	Mouse colon carcinoma	10 mg/kg Q3Dx7 (day 3)	0.50*	n.d.	n.d.
CT26	BALB/c	Mouse colon carcinoma	3 mg/kg ^b Q3Dx3 (day 8)	0.95	0.64*	0.38***
MBT-2	C3H	Mouse bladder carcinoma	10 mg/kg Q3Dx4 (day 13)	0.61*	n.d.	n.d.

^a BAY 1905254 dose, anti-PD-L1 3 mg/kg

^b BAY 1905254 dose, anti-PD-L1 10 mg/kg

*, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$, compared to isotype control

n.d., not determined; Q3D, every 3rd day, T/C, treatment vs. control ratio